Candel Therapeutics (CADL) pipeline and stated timing

Name in SEC filings: Candel Therapeutics, Inc.

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
aglatimagene besadenovec	submission	—	fourth quarter of 2026	8-K · Sep 10, 2026
linoserpaturev	/data readout	Stage not stated	fourth quarter of 2026	10-Q · Aug 13, 2026

Source: ORION, orionbiotechai.com/company/CADL, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/CADL

Nearest upcoming stated timing: aglatimagene besadenovec · NDA/BLA submission · fourth quarter of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

aglatimagene besadenovec

Matched

NDA/BLA submissionfourth quarter of 2026

Stage: —

Public float: $245,300,000 · as of Jun 30, 2025 · SEC filing

planned submission of the BLA for aglatimagene besadenovec in the fourth quarter of 2026

8-K · Filed Sep 10, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-387310

Alert me · Calendar: same stage and window-end month (2026-12)

linoserpaturev

Matched

Topline/data readoutfourth quarter of 2026

Stage: Not stated

Public float: $245,300,000 · as of Jun 30, 2025 · SEC filing

We expect to present data on potential long-term survivors in the fourth quarter of 2026.

10-Q · Filed Aug 13, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001193125-26-347980

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
aglatimagene besadenovecSubmission	fourth quarter of 2026 “planned submission of the BLA for aglatimagene besadenovec in the fourth quarter of 2026” Filed Sep 10, 2026 · EX-99.1	Still within period As of Oct 19, 2026
aglatimagene besadenovecSubmission	2026 “The campaign is progressing well and is a critical CMC activity to enable the anticipated BLA submission in Q4 2026.” Filed Aug 13, 2026 · EX-99.1	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
linoserpaturevClinical results	fourth quarter of 2026 “We expect to present data on potential long-term survivors in the fourth quarter of 2026.” Filed Aug 13, 2026 · 10-Q	Still within period As of Oct 19, 2026
linoserpaturevClinical results	fourth quarter of 2026 “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” Filed May 14, 2026 · 10-Q	Still within period As of Oct 19, 2026
linoserpaturevClinical results	fourth quarter of 2026 “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” Filed Mar 12, 2026 · 10-K	Still within period As of Oct 19, 2026
aglatimagene besadenovecSubmission	fourth quarter of 2026 “anticipated submission of a Biologics License Application for CAN-2409 in prostate cancer in the fourth quarter of 2026.” Filed Nov 13, 2025 · 10-Q	Still within period As of Oct 19, 2026
linoserpaturevClinical results	fourth quarter of 2026 “expect to present mature mOS data and an update on long-term survivors in the fourth quarter of 2026” Filed Nov 13, 2025 · 10-Q	Still within period As of Oct 19, 2026
aglatimagene besadenovecSubmission	fourth quarter of 2026 “we anticipate submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.” Filed Aug 14, 2025 · 10-Q	Still within period As of Oct 19, 2026
aglatimagene besadenovecSubmission	fourth quarter of 2026 “we anticipate submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.” Filed May 13, 2025 · 10-Q	Still within period As of Oct 19, 2026

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch CADL

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for CADL. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See CADL in the calendar · Review labels and methodology